84
Views
1
CrossRef citations to date
0
Altmetric
Original Research

A 3-day regimen with azithromycin 1.5% eyedrops for the treatment of purulent bacterial conjunctivitis in children: efficacy on clinical signs and impact on the burden of illness

, , , , &
Pages 725-732 | Published online: 20 Apr 2015

Figures & data

Table 1 Patient demographics (full analysis set)

Figure 1 Evolution of cardinal signs of bacterial conjunctivitis.

Notes: (A) Bulbar conjunctival hyperemia; (B) purulent conjunctival discharge. Microbiologically positive full analysis set. Azithromycin group: (AZIT): N=102 on day 0, N=101 on day 3, N=96 on day 7; tobramycin group (TOBRA): N=101 on day 0, day 3, and day 7. Data presented from the worse eye.
Figure 1 Evolution of cardinal signs of bacterial conjunctivitis.

Figure 2 Global efficacy assessment by the investigator.

Notes: (A) Day 3; (B) day 7. Microbiologically positive full analysis set. Azithromycin group: N=99 at day 3 and N=95 at day 7; tobramycin group: N=100 on day 3 and day 7. Data presented from the worse eye.
Figure 2 Global efficacy assessment by the investigator.

Figure 3 Number of days that an improvement was felt.

Notes: Microbiologically positive full analysis set; 65 patients in the azithromycin group and 56 patients in the tobramycin group.
Figure 3 Number of days that an improvement was felt.

Figure 4 Ease of treatment and impact on daily life.

Notes: (A) Treatment duration (P<0.001). (B) Easiness of instilling drops during the day (P<0.001). (C) Easiness of respecting the prescribed number of instillations (P<0.001). (D) Difficulty of performing usual activities (P<0.001). (Full analysis set population: 84 patients in the azithromycin group and 75 patients in the tobramycin group).
Figure 4 Ease of treatment and impact on daily life.

Table 2 Summary of questionnaire results among infants (aged less than 24 months)